Literature DB >> 11020253

Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

N Rastogi1, K S Goh, M Berchel, A Bryskier.   

Abstract

The in vitro activity of rifapentine and its metabolite, 25-O:-desacetylrifapentine, as compared with that of rifampicin and rifabutin, was determined against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. MICs were determined radiometrically and by the 1% proportional method using Middlebrook 7H11 agar. The bactericidal effect of the drugs was determined in parallel at selected concentrations. For drugsusceptible isolates of M. tuberculosis, the Bactec MICs of rifapentine and 25-O:-desacetylrifapentine were 0.03-0.06 mg/L and 0. 125-0.25 mg/L, respectively. Similar MICs were obtained for M. africanum (0.03-0.125 and 0.125-0.50 mg/L, respectively), and M. bovis (0.063-0.25 and 0.125-1.0 mg/L, respectively), but MICs were considerably lower for M. bovis BCG (0.008-0.063 mg/L for rifapentine and 0.016-0.125 mg/L for its metabolite). In general, MICs determined using 7H11 agar medium were usually one or two dilutions higher than those obtained using Bactec broth. When compared with rifampicin and rifabutin, the inhibitory activity of rifapentine for drug-susceptible isolates was roughly equal to that of rifabutin, and the inhibitory activity of 25-O:-desacetylrifapentine was comparable to that of rifampicin; however, rifapentine was somewhat more bactericidal than rifabutin at equal concentrations. Clinical isolates of M. tuberculosis with a high degree of resistance to rifampicin (MIC >/= 32 mg/L) were also highly resistant to rifabutin, rifapentine and 25-O:-desacetylrifapentine, although the MICs of rifabutin in this case were somewhat lower than the MICs of rifapentine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020253     DOI: 10.1093/jac/46.4.565

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.

Authors:  Nicole Ritz; Marc Tebruegge; Tom G Connell; Aina Sievers; Roy Robins-Browne; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

2.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 3.  Rifamycins, Alone and in Combination.

Authors:  David M Rothstein
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

4.  Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

Authors:  Todd J Zurlinden; Garrett J Eppers; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.

Authors:  Noton K Dutta; Abdullah Alsultan; Charles A Peloquin; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

6.  Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.

Authors:  Eric F Egelund; Marc Weiner; Rajendra P Singh; Thomas J Prihoda; Jonathon A L Gelfond; Hartmut Derendorf; William R Mac Kenzie; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

7.  Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.

Authors:  Grant Langdon; Justin Wilkins; Lynn McFadyen; Helen McIlleron; Peter Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  Novel genetic polymorphisms that further delineate the phylogeny of the Mycobacterium tuberculosis complex.

Authors:  Richard C Huard; Michel Fabre; Petra de Haas; Luiz Claudio Oliveira Lazzarini; Dick van Soolingen; Debby Cousins; John L Ho
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

Review 9.  Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.

Authors:  Mario Regazzi; Anna Cristina Carvalho; Paola Villani; Alberto Matteelli
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

10.  Rifapentine Polylactic Acid Sustained-Release Microsphere Complex for Spinal Tuberculosis Therapy: Preparation, in vitro and in vivo Studies.

Authors:  Zhen Wang; Xinghua Song; Abulikemu Maimaitiaili; Tengfei Wang
Journal:  Infect Drug Resist       Date:  2021-05-14       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.